Lipocine’s oral brexanolone just blew up. The Utah biotech’s Phase 3 trial for its postpartum depression drug — LPCN 1154 — missed the mark, sending shares down 77% in a single session.
That’s a brutal result for a drug that was supposed to be a more convenient version of Zulresso, Sage Therapeutics’ IV brexanolone. The pitch was simple: same mechanism, oral pill, no hospital infusion. That would have expanded access to a drug that currently requires hospital admission.
The Phase 3 failure kills that thesis entirely. Oral bioavailability of brexanolone is notoriously tricky — it’s a neurosteroid that doesn’t play well with gut metabolism — and apparently Lipocine couldn’t crack it at the efficacy level regulators would accept. That’s the core problem: IV delivery works. Oral doesn’t, at least not here. Lipocine wasn’t unaware of the bioavailability challenge; apparently it also couldn’t solve it.
Celldex and Pfizer both had clinical news the same day. Neither moved the market the way LPCN 1154 did. No path forward has been announced for Lipocine. The 77% drop is the market’s answer to what comes next.
The FDA had not approved LPCN 1154; there was no NDA to withdraw.
— Sarah Chen